PRESS RELEASE published on 12/20/2024 at 07:00, 11 months 16 days ago Inside Information / Other news releases Innate Pharma to participate in the 43rd Annual J.P. Morgan Healthcare Conference with CEO Jonathan Dickinson and other executives presenting. Company focuses on developing immunotherapies for cancer patients Biotechnology Innate Pharma Immunothérapies Cancer Patients J.P. Morgan Healthcare Conference
BRIEF published on 12/06/2024 at 07:05, 11 months 30 days ago Innate Pharma: Investment of 7.9 million dollars for IPH6501 Investment Clinical Trial Innate Pharma IPH6501 Follicular Lymphoma
BRIEF published on 11/20/2024 at 07:05, 1 year ago Innate Pharma unveils its financial calendar for 2025 Annual Results Innate Pharma Financial Calendar 2025 Assemblies And Publications Euronext And Nasdaq Contribution
PRESS RELEASE published on 11/20/2024 at 07:00, 1 year ago Inside Information / Other news releases Innate Pharma releases its 2025 financial calendar including key publication dates for financial statements and shareholder meetings Financial Statements Investors Financial Calendar 2025 Innate Pharma
BRIEF published on 11/08/2024 at 07:05, 1 year ago Innate Pharma presents its innovations in oncology at SITC 2024 Immunotherapy Innate Pharma SITC 2024 NK Cell Engage Antibody-drug Conjugate
PRESS RELEASE published on 11/08/2024 at 07:00, 1 year ago Inside Information / Other news releases Innate Pharma announces new preclinical data on IPH6501 and IPH4502 to be presented at SITC Annual Meeting 2024. Advances in immunotherapy reflected in drug development progress Drug Development Preclinical Data Immunotherapy Innate Pharma SITC Annual Meeting 2024
BRIEF published on 06/17/2024 at 07:05, 1 year 5 months ago Innate Pharma reveals promising results for SAR443579/IPH6101 in blood cancers Sanofi Innate Pharma SAR443579 Leukemia Blood Cancer
PRESS RELEASE published on 06/17/2024 at 07:00, 1 year 5 months ago Inside Information / Other news releases Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial, showing promising clinical efficacy and safety in patients with R/R AML Sanofi Innate Pharma Blood Cancer NK Cell Engager Phase 1/2 Trial
BRIEF published on 05/28/2024 at 07:05, 1 year 6 months ago Innate Pharma announces its participation in upcoming investor conferences Biotechnology Investor Conferences Immunotherapy Health Innate Pharma
BRIEF published on 05/23/2024 at 22:05, 1 year 6 months ago Results of the Combined General Meeting of Innate Pharma Voting Results Supervisory Board General Assembly Innate Pharma
Published on 12/05/2025 at 02:35, 4 hours 36 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 11 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 6 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 11 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 11 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 40 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 20 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 45 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 56 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:00, 13 hours 11 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 26 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 27 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago Declaration of voting rights at the end of November 2025
